Accurate detection is essential to prevent misdiagnosis and ensure the right treatment, particularly in cases involving drug-resistant TB or NTM infections. The Hi-PCR ® MTB/NTM Probe PCR Kit ...

The U.S. Food and Drug Administration (FDA) has cleared the first blood test to aid in diagnosis of Alzheimer's disease. The test detects amyloid plaques, a hallmark of Alzheimer's disease, through a ...

New research presented today at the European Stroke Organisation Conference (ESOC) 2025 revealed that the use of combined oral contraceptives (OCs) is associated with a threefold increase in the risk ...

In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $99.0, a ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the ...

Insmed (INSM) is at a critical point. While its revenue stream is from ARIKAYCE for Mycobacterium Avium Complex lung disease, the company's future and potential share price appreciation are ...

abscessus infections are subject to drug-to-drug ... nontuberculous mycobacteria (NTM), as well as against Mycobacterium avium complex (MAC), and TB. M. abscessus remains the primary target.

INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.

NTM infection is a rare and serious bacterial ... of Mycobacterium abscessus complex (MABSC) and refractory Mycobacterium avium complex (MAC) and may cause severe adverse events.

which is approved for treating refractory mycobacterium avium complex (“MAC”) lung disease in adults with limited or no alternative treatment options. The rise in Arikayce sales was driven by ...